الإحصائيات الأساسية
| LEI | 894500UZJ5LG1F8J1U58 |
| CIK | 1776985 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to BioNTech SE - Depositary Receipt (Common Stock)
SEC Filings (Chronological Order)
توفر هذه الصفحة قائمة كاملة ومرتبة ترتيبًا زمنيًا لتصريحات هيئة الأوراق المالية والبورصات، باستثناء تصريحات الملكية التي نقدمها في مكان آخر.
| September 5, 2025 |
Exhibit 99.1 BioNTech and DualityBio Announce Phase 3 Trial of ADC Candidate BNT323/DB-1303 Met Primary Endpoint of Progression Free Survival in HER2-Positive Metastatic or Unresectable Breast Cancer •Trastuzumab pamirtecan (BNT323/DB-1303), an investigational next-generation antibody drug-conjugate (“ADC”) targeting HER-2, met its primary endpoint of progression free survival (“PFS”) in interim a |
|
| September 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF SEPTEMBER 2025 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant’s name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal execu |
|
| August 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF AUGUST 2025 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant’s name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal executiv |
|
| August 27, 2025 |
Exhibit 99.1 Pfizer and BioNTech’s COMIRNATY® Receives U.S. FDA Approval for Adults 65 and Older and Individuals Ages 5 through 64 at Increased Risk for Severe COVID-19 •The 2025-2026 COVID-19 vaccine formulation targets the SARS-CoV-2 sublineage LP.8.1, in line with FDA guidance to more closely match circulating strains1 •Shipping of the LP.8.1-adapted vaccine will begin immediately to ensure rob |
|
| August 11, 2025 |
Calculation of Filing Fee Tables F-4 BioNTech SE Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effective Date Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to be Paid 1 Equity Ordinary shares, no par value Other 14,582,187 $ 1,227,191,482. |
|
| August 11, 2025 |
EX-99.2 Exhibit 99.2 Offer to Exchange each outstanding ordinary share of CureVac N.V. for $5.4641 of American Depositary Shares of BioNTech SE (subject to a collar and calculated as described in the Exchange Offer Prospectus) THE EXCHANGE OFFER (AS DEFINED BELOW) AND WITHDRAWAL RIGHTS WILL EXPIRE AT 9:00 A.M., NEW YORK CITY TIME, ON [●], 2025, UNLESS THE EXCHANGE OFFER IS EXTENDED OR TERMINATED ( |
|
| August 11, 2025 |
EX-99.1 Exhibit 99.1 DRAFT—the offer has not yet commenced. DESCRIPTION OF SHARES TENDERED Name(s) and Address(es) of Registered Holder(s) Total Number of Share(s) Tendered* * Unless otherwise indicated, it will be assumed that all shares presented with this Letter of Transmittal, along with all shares held as book-entry within the account are being tendered hereby. If the indicated number exceed |
|
| August 11, 2025 |
EX-99.3 Exhibit 99.3 Offer to Exchange each outstanding ordinary share of CureVac N.V. for $5.4641 of American Depositary Shares of BioNTech SE (subject to a collar and calculated as described in the Exchange Offer Prospectus) THE EXCHANGE OFFER (AS DEFINED BELOW) AND WITHDRAWAL RIGHTS WILL EXPIRE AT 9:00 A.M., NEW YORK CITY TIME, ON [●], 2025, UNLESS THE EXCHANGE OFFER IS EXTENDED OR TERMINATED ( |
|
| August 11, 2025 |
425 Filed by BioNTech SE (Commission File No. 001-39081) pursuant to Rule 425 under the Securities Act of 1933, as amended and deemed filed pursuant to Rule 14d-2(b) under the Securities Exchange Act of 1934, as amended. Subject Company: CureVac N.V. Commission File No.: 001-39446 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURS |
|
| August 11, 2025 |
F-4 Table of Contents Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-4 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BIONTECH SE (Exact name of Registrant as specified in its charter) Federal Republic of Germany 2836 98-151-1032 (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classifica |
|
| August 11, 2025 |
EX-99.4 Exhibit 99.4 Notice of Withdrawal to withdraw ordinary shares of CureVac N.V. in the Offer to Exchange each outstanding ordinary share of CureVac N.V. for $5.4641 of American Depositary Shares of BioNTech SE (subject to a collar and calculated as described in the Exchange Offer Prospectus) THE EXCHANGE OFFER (AS DEFINED BELOW) AND WITHDRAWAL RIGHTS WILL EXPIRE AT 9:00 A.M., NEW YORK CITY T |
|
| August 11, 2025 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF AUGUST 2025 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant’s name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal exec |
|
| August 8, 2025 |
Filed by BioNTech SE (Commission File 425 Filed by BioNTech SE (Commission File No. 001-39081) pursuant to Rule 425 under the Securities Act of 1933, as amended and deemed filed pursuant to Rule 14d-2(b) under the Securities Exchange Act of 1934, as amended. Subject Company: CureVac N.V. Commission File No.: 001-39446 The following communications are being filed in connection with the proposed acquisition of CureVac N.V. by BioNTech S |
|
| August 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF AUGUST 2025 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant’s name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal executiv |
|
| August 4, 2025 |
a992bntxq22025presentati 2nd Quarter 2025 Financial Results & Corporate Update August 4th, 2025 Exhibit 99. |
|
| August 4, 2025 |
BioNTech Announces Second Quarter 2025 Financial Results and Corporate Update Exhibit 99.1 BioNTech Announces Second Quarter 2025 Financial Results and Corporate Update •Continued execution of BioNTech’s oncology strategy with focus on two pan-tumor programs including two announced transactions: mRNA-based cancer immunotherapy candidates and BNT327, a bispecific antibody candidate targeting PD-L11 and VEGF-A •Entered a global strategic co-development and co-commercializatio |
|
| August 4, 2025 |
Exhibit 99.1 Our principal executive offices are located at An der Goldgrube 12, D-55131 Mainz, Germany. Our telephone number is +49 6131-9084-0. Our website address is www.biontech.com. The information contained on, or that can be accessed through, our website is not part of this document. Our agent for service solely for the purpose of notices and communications from the Securities and Exchange |
|
| August 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF AUGUST 2025 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant’s name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal executiv |
|
| July 25, 2025 |
Exhibit 99.1 Pfizer and BioNTech Receive Positive CHMP Opinion for LP.8.1-Adapted COVID-19 Vaccine in the European Union •Data indicate that the LP.8.1-adapted COVID-19 vaccine confers improved immune response against currently dominant and emerging sublineages – including the XFG and NB.1.8.1 variants1 – compared to 2024-2025 COVID-19 vaccine formulations •Upon authorization by the European Commi |
|
| July 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF JULY 2025 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant’s name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal executive |
|
| July 17, 2025 |
BioNTech Announces Ryan Richardson to Step Down from the Management Board Exhibit 99.1 BioNTech Announces Ryan Richardson to Step Down from the Management Board MAINZ, Germany, July 17, 2025 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today that Ryan Richardson will step down as Chief Strategy Officer in the Management Board of BioNTech on September 30, 2025, and as a Board Director at affiliated companies of the BioNTech Group b |
|
| July 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF JULY 2025 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant’s name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal executive |
|
| June 30, 2025 |
EX-99.4 Exhibit 99.4 Notice of Withdrawal to withdraw ordinary shares of CureVac N.V. in the Offer to Exchange each outstanding ordinary share of CureVac N.V. for $5.4641 of American Depositary Shares of BioNTech SE (subject to a collar and calculated as described in the Exchange Offer Prospectus) THE EXCHANGE OFFER (AS DEFINED BELOW) AND WITHDRAWAL RIGHTS WILL EXPIRE AT 9:00 A.M., NEW YORK CITY T |
|
| June 30, 2025 |
EX-99.3 Exhibit 99.3 Offer to Exchange each outstanding ordinary share of CureVac N.V. for $5.4641 of American Depositary Shares of BioNTech SE (subject to a collar and calculated as described in the Exchange Offer Prospectus) THE EXCHANGE OFFER (AS DEFINED BELOW) AND WITHDRAWAL RIGHTS WILL EXPIRE AT 9:00 A.M., NEW YORK CITY TIME, ON [●], 2025, UNLESS THE EXCHANGE OFFER IS EXTENDED OR TERMINATED ( |
|
| June 30, 2025 |
EX-99.2 Exhibit 99.2 Offer to Exchange each outstanding ordinary share of CureVac N.V. for $5.4641 of American Depositary Shares of BioNTech SE (subject to a collar and calculated as described in the Exchange Offer Prospectus) THE EXCHANGE OFFER (AS DEFINED BELOW) AND WITHDRAWAL RIGHTS WILL EXPIRE AT 9:00 A.M., NEW YORK CITY TIME, ON [●], 2025, UNLESS THE EXCHANGE OFFER IS EXTENDED OR TERMINATED ( |
|
| June 30, 2025 |
DESCRIPTION OF SHARES TENDERED EX-99.1 Exhibit 99.1 DESCRIPTION OF SHARES TENDERED Name(s) and Address(es) of Registered Holder(s) Total Number of Share(s) Tendered* * Unless otherwise indicated, it will be assumed that all shares presented with this Letter of Transmittal, along with all shares held as book-entry within the account are being tendered hereby. If the indicated number exceeds the number of book-entry shares withi |
|
| June 30, 2025 |
DRS Table of Contents As confidentially submitted to the Securities and Exchange Commission on June 30, 2025. |
|
| June 17, 2025 |
ARTICLES OF ASSOCIATION OF BIONTECH SE Convenience Translation. The German version is authoritative Exhibit 99.1 E ARTICLES OF ASSOCIATION OF BIONTECH SE I.General Provisions § 1Company Name, Registered Office and Financial Year (1)The name of the Company is “BioNTech SE”. (2)The Company has its registered office in Mainz, Germany. (3)The financial year is the calendar year. § 2Purpose of Enterprise (1)The purpose of the Company is the |
|
| June 17, 2025 |
425 Filed by BioNTech SE (Commission File No. 001-39081) pursuant to Rule 425 under the Securities Act of 1933, as amended and deemed filed pursuant to Rule 14d-2(b) under the Securities Exchange Act of 1934, as amended. Subject Company: CureVac N.V. Commission File No.: 001-39446 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURS |
|
| June 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF JUNE 2025 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant’s name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal executive |
|
| June 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF JUNE 2025 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant’s name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal executive |
|
| June 17, 2025 |
PURCHASE AGREEMENT dated as of June 12, 2025 by and between BIONTECH SE CUREVAC N.V. Exhibit 99.1 Execution Version PURCHASE AGREEMENT dated as of June 12, 2025 by and between BIONTECH SE and CUREVAC N.V. TABLE OF CONTENTS Page Article 1 DEFINITIONS Section 1.01 Definitions 2 Section 1.02 Other Definitional and Interpretative Provisions 18 Article 2 THE OFFER Section 2.01 The Offer 18 Section 2.02 Company Action 22 Section 2.03 Equity Awards 23 Section 2.04 Extraordinary General M |
|
| June 12, 2025 |
Filed by BioNTech SE (Commission File Filed by BioNTech SE (Commission File No. 001-39081) pursuant to Rule 425 under the Securities Act of 1933, as amended and deemed filed pursuant to Rule 14d-2(b) under the Securities Exchange Act of 1934, as amended. Subject Company: CureVac N.V. Commission File No.: 001-39446 The following communications are being filed in connection with the proposed acquisition of CureVac N.V. by BioNTech SE. A |
|
| June 12, 2025 |
Filed by BioNTech SE (Commission File Filed by BioNTech SE (Commission File No. 001-39081) pursuant to Rule 425 under the Securities Act of 1933, as amended and deemed filed pursuant to Rule 14d-2(b) under the Securities Exchange Act of 1934, as amended. Subject Company: CureVac N.V. Commission File No.: 001-39446 The following communications are being filed in connection with the proposed acquisition of CureVac N.V. by BioNTech SE. C |
|
| June 12, 2025 |
BioNTech Announces Strategic Transaction to Acquire CureVac in Public Exchange Offer Exhibit 99.1 BioNTech Announces Strategic Transaction to Acquire CureVac in Public Exchange Offer • Acquisition will strengthen the research, development, manufacturing and commercialization of mRNA-based cancer immunotherapy candidates, marking BioNTech’s next key milestone in the execution of its oncology strategy • Acquisition of CureVac will complement BioNTech’s capabilities and proprietary t |
|
| June 12, 2025 |
Filed by BioNTech SE (Commission File Filed by BioNTech SE (Commission File No. 001-39081) pursuant to Rule 425 under the Securities Act of 1933, as amended and deemed filed pursuant to Rule 14d-2(b) under the Securities Exchange Act of 1934, as amended. Subject Company: CureVac N.V. Commission File No.: 001-39446 The following communications are being filed in connection with the proposed acquisition of CureVac N.V. by BioNTech SE. D |
|
| June 12, 2025 |
425 Filed by BioNTech SE (Commission File No. 001-39081) pursuant to Rule 425 under the Securities Act of 1933, as amended and deemed filed pursuant to Rule 14d-2(b) under the Securities Exchange Act of 1934, as amended. Subject Company: CureVac N.V. Commission File No.: 001-39446 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURS |
|
| June 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF JUNE 2025 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant’s name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal executive |
|
| June 12, 2025 |
BioNTech Acquisition of CureVac Questions & Answers Filed by BioNTech SE (Commission File No. 001-39081) pursuant to Rule 425 under the Securities Act of 1933, as amended and deemed filed pursuant to Rule 14d-2(b) under the Securities Exchange Act of 1934, as amended. Subject Company: CureVac N.V. Commission File No.: 001-39446 The following communications are being filed in connection with the proposed acquisition of CureVac N.V. by BioNTech SE. B |
|
| June 2, 2025 |
A Transformative Global Partnership for BNT327 (PD-L1 x VEGF-A bispecific antibody) June 2, 2025 Exhibit 99. |
|
| June 2, 2025 |
Exhibit 99.1 BioNTech and Bristol Myers Squibb Announce Global Strategic Partnership to Co-Develop and Co-Commercialize Next-generation Bispecific Antibody Candidate BNT327 Broadly for Multiple Solid Tumor Types •BNT327, BioNTech’s PD-L1xVEGF-A bispecific antibody, is a clinically advanced investigational immunotherapy candidate with the potential to surpass current checkpoint inhibitor outcomes a |
|
| June 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF JUNE 2025 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant’s name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal executive |
|
| May 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF MAY 2025 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant’s name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal executive o |
|
| May 27, 2025 |
BioNTech to Present Progress Across Diversified Oncology Pipeline at the 2025 ASCO Annual Meeting Exhibit 99.1 BioNTech to Present Progress Across Diversified Oncology Pipeline at the 2025 ASCO Annual Meeting MAINZ, Germany, May 27, 2025 - BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present clinical trial data from select pipeline candidates across the Company’s diversified oncology portfolio at the American Society of Clinical Oncology (“ASCO”) Annual Meeting, to be held in C |
|
| May 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF MAY 2025 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant’s name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal executive o |
|
| May 20, 2025 |
Exhibit 99.1 BioNTech Expands Partnership with UK Government to Broaden Regional Research and Development Activities •BioNTech plans to invest up to £1 billion over the next 10 years to broaden its research and development activities for innovative medicines in the United Kingdom (“UK”) •The UK Government will give BioNTech a grant of up to £129 million payable over a period of 10 years to support |
|
| May 16, 2025 |
a992biontechse-agm2025xv Voting results - Overview BioNTech SE, Mainz ordinary Annual General Meeting on 16/05/2025 Page 1Note: Percentages rounded to 2 decimal places Valid votes cast Yes votes No votes Item Shares % of capital stock Shares % Shares % Item 2 Resolution on the appropriation of the balance sheet profit for the 2024 financial year 236,723,942 95. |
|
| May 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF MAY 2025 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant’s name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal executive o |
|
| May 16, 2025 |
a991agmpresentationengx Annual General Meeting 16 May 2025, 14:00 CET Exhibit 99.1 Management Report 2 1 Operations Development 2024 & Q1 2025 and Outlook 2025 Prof. Dr. Ugur Sahin, Chief Executive Officer & Co-Founder Financial Development 2024 & Q1 2025 and Financial Outlook 2025 Jens Holstein, Chief Financial Officer Operations Development 2024 & Q1 2025 and Outlook 2025 Prof. Dr. Ugur Sahin, C |
|
| May 5, 2025 |
BioNTech Announces Appointment of Ramón Zapata to Management Board as Chief Financial Officer Exhibit 99.1 BioNTech Announces Appointment of Ramón Zapata to Management Board as Chief Financial Officer Mainz, Germany, May 5, 2025 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today that the Supervisory Board has appointed Ramón Zapata-Gomez to the Management Board as Chief Financial Officer (“CFO”) effective July 1, 2025. He will join BioNTech from Nova |
|
| May 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF MAY 2025 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant’s name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal executive o |
|
| May 5, 2025 |
May 5th, 2025 1st Quarter 2025 Financial Results & Corporate Update Exhibit 99.2 2 This Slide Presentation Includes Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: BioNTech’s expected revenues and net profit/(loss) related to |
|
| May 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF MAY 2025 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant’s name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal executive o |
|
| May 5, 2025 |
Exhibit 99.1 Our principal executive offices are located at An der Goldgrube 12, D-55131 Mainz, Germany. Our telephone number is +49 6131-9084-0. Our website address is www.biontech.com. The information contained on, or that can be accessed through, our website is not part of this document. Our agent for service solely for the purpose of notices and communications from the Securities and Exchange |
|
| May 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF MAY 2025 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant’s name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal executive o |
|
| May 5, 2025 |
BioNTech Announces First Quarter 2025 Financial Results and Corporate Update Exhibit 99.1 BioNTech Announces First Quarter 2025 Financial Results and Corporate Update •Continued oncology pipeline advancement with a strategic focus on two priority pan-tumor programs: next-generation immunomodulator BNT327, a bispecific antibody targeting PD-L1 and VEGF-A1, and mRNA cancer immunotherapies •Presented multiple clinical updates across oncology pipeline underlining BioNTech’s co |
|
| April 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF APRIL 2025 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant’s name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal executive |
|
| April 24, 2025 |
Exhibit 99.1 BioNTech to Present Clinical and Preclinical Data Across mRNA and Next-Generation Immuno-Oncology Priority Programs at AACR 2025 MAINZ, Germany, April 24, 2025 - BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present data for selected assets from its diversified oncology pipeline, including mRNA cancer immunotherapies, next-generation immunomodulators, and targeted thera |
|
| April 4, 2025 |
Exhibit 99.1 English Convenience Translation – the German language version is decisive BioNTech SE Mainz WKN A0V9BC | ISIN DE000A0V9BC4 WKN: A2PSR2 | ISIN: US09075V1026 Invitation to the Annual General Meeting 2025 Unique identifier of the event: 6b7baf20e5eaef11b53e00505696f23c Ladies and Gentlemen, We hereby invite our shareholders1 to the Annual General Meeting of BioNTech SE, Mainz, (the “Comp |
|
| April 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF APRIL 2025 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant’s name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal executive |
|
| April 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF APRIL 2025 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant’s name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal executive |
|
| March 10, 2025 |
Exhibit 4.55 [***] Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) the type of information that the Registrant treats as private or confidential. Confidential EXECUTION AGREEMENT AND PLAN OF MERGER by and among BIONTECH COLLABORATIONS GMBH, MERGER SUB, BIOTHEUS and SHAREHOLDER REPRESENTATIVE SERVICES LLC, solely in its capacity a |
|
| March 10, 2025 |
Exhibit 4.56 [***] Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) the type of information that the Registrant treats as private or confidential. EXECUTION VERSION PUBLIC HEALTH SERVICE Amended and Restated Agreement This amended and restated agreement (“Amended and Restated Agreement”) is based on the model “Patent License Non-E |
|
| March 10, 2025 |
A C T I N G T O G E T H E R — C R E A T I N G S Y N E R G I E S A C T I N G T O G E T H E R — C R E A T I N G S Y N E R G I E S BioNTech SE Annual Report on Form 20-F for the year ended December 31, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 10, 2025 |
Consent of Independent Registered Public Accounting Firm Exhibit 15.1 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the following Registration Statements: (1)Registration Statement (Form S-8 No. 333-253263) pertaining to the 2020 Employee Equity Plan, the 2020 Restricted Stock Unit Plan for North America Employees, the 2017 Employee Stock Ownership Plan and the 2020 Management Board ESOP of BioN |
|
| March 10, 2025 |
Exhibit 12.2 CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Jens Holstein, certify that: 1.I have reviewed this annual report on Form 20-F of BioNTech SE; 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material |
|
| March 10, 2025 |
Exhibit 12.1 CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Ugur Sahin, certify that: 1.I have reviewed this annual report on Form 20-F of BioNTech SE; 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fa |
|
| March 10, 2025 |
Exhibit 13.2 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 The certification set forth below is being submitted in connection with the Annual Report on Form 20-F for the year ended 2024 (the “Report”) for the purpose of complying with Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 (the “Exchange Act”) |
|
| March 10, 2025 |
Exhibit 2.4 DESCRIPTION OF SECURITIES The following description sets forth certain material terms and provisions of ordinary shares and American Depositary Shares representing ordinary shares of BioNTech SE (“BioNTech,” the “Company,” “we,” “us,” and “our”) that are registered under Section 12 of the U.S. Securities Exchange Act of 1934, as amended. This description also summarizes certain provisi |
|
| March 10, 2025 |
Exhibit 11.1 [***] Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) the type of information that the Registrant treats as private or confidential. INSIDER TRADING POLICY [***] Insider Trading Policy Table of Contents 1. Introduction 3 2. Applicability 3 3. Material Non-Public Information 3 4. General Requirements 4 a) General Proh |
|
| March 10, 2025 |
BioNTech Announces Fourth Quarter and Full Year 2024 Financial Results and Corporate Update Exhibit 99.1 BioNTech Announces Fourth Quarter and Full Year 2024 Financial Results and Corporate Update •Advanced oncology pipeline including more than 20 active Phase 2 and Phase 3 clinical trials with a strategic focus on two priority pan-tumor programs: next-generation immunomodulator candidate BNT327 and mRNA cancer immunotherapies •Multiple data readouts expected in 2025 and 2026 aimed at pr |
|
| March 10, 2025 |
March 10, 2025 4th Quarter and Full Year 2024 Financial Results & Corporate Update Exhibit 99. |
|
| March 10, 2025 |
Exhibit 4.54 [***] Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) the type of information that the Registrant treats as private or confidential. Confidential Execution Version BioNTech SE · An der Goldgrube 12 · 55131 Mainz Germany Reference number: Contact: Department: [***] [***] [***] Phone: Fax: Email: Website: [***] [***] [ |
|
| March 10, 2025 |
Exhibit 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 The certification set forth below is being submitted in connection with the Annual Report on Form 20-F for the year ended 2024 (the “Report”) for the purpose of complying with Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 (the “Exchange Act”) |
|
| March 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF MARCH 2025 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant’s name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal executive |
|
| March 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF MARCH 2025 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant’s name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal executive |
|
| February 3, 2025 |
BioNTech Completes Acquisition of Biotheus Exhibit 99.1 BioNTech Completes Acquisition of Biotheus •Acquisition to strengthen key pillar of BioNTech’s oncology strategy aimed at establishing BNT327 as a pan-tumor technology platform for the treatment of advanced cancers •With the closing of the transaction, BioNTech will expand its capabilities to develop, manufacture and commercialize novel BNT327 combinations and next-generation bispecif |
|
| February 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF FEBRUARY 2025 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant’s name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal execut |
|
| January 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF JANUARY 2025 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant’s name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal executi |
|
| January 14, 2025 |
43rd J.P. Morgan Healthcare Conference Prof. Ugur Sahin, M.D. CEO & Co-founder 14 January 2025 9:00 – 9:40 AM PST Exhibit 99.2 This Slide Presentation Includes Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: BioNTech’s expect |
|
| January 14, 2025 |
BioNTech provides business and pipeline updates at 43rd annual J.P. Morgan Healthcare Conference Exhibit 99.1 BioNTech provides business and pipeline updates at 43rd annual J.P. Morgan Healthcare Conference •Executing in oncology with investigational BNT327/PM8002 combinations and mRNA cancer immunotherapy candidates as pan-tumor treatment approaches •BioNTech aims to develop BNT327/PM8002 as a next-generation immuno-oncology (“IO”) backbone for the Company’s combination strategy targeting a |
|
| December 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF DECEMBER 2024 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant’s name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal execut |
|
| December 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF DECEMBER 2024 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant’s name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal execut |
|
| December 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF DECEMBER 2024 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant’s name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal execut |
|
| November 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF NOVEMBER 2024 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant’s name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal execut |
|
| November 14, 2024 |
Innovation Series 2024 November 14, 2024 10:30 AM – 2:15 PM ET Exhibit 99.1 1 Welcome & Introductory Remarks Ryan Richardson, Chief Strategy Officer This Slide Presentation Includes Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concern |
|
| November 13, 2024 |
BNTX / BioNTech SE - Depositary Receipt (Common Stock) / ATHOS KG - SC 13G/A Passive Investment SC 13G/A 1 d839798dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5)* BIONTECH SE (Name of Issuer) Ordinary Shares, no par value per share (€1.00 nominal amount) (including Ordinary Shares represented by American Depositary Shares) (Title of Class of Securities) 09075V102** (CUSIP Nu |
|
| November 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF NOVEMBER 2024 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant’s name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal execut |
|
| November 13, 2024 |
BioNTech to Acquire Biotheus to Boost Oncology Strategy Exhibit 99.1 BioNTech to Acquire Biotheus to Boost Oncology Strategy •Acquisition to support the global execution of BioNTech’s oncology strategy and provide full global rights to BNT327/PM8002, an investigational PD-L1 x VEGF-A bispecific antibody, with potential to replace current checkpoint inhibitor standard of care treatments for solid tumors •With the acquisition of Biotheus, BioNTech aims t |
|
| November 4, 2024 |
ARTICLES OF ASSOCIATION OF BIONTECH SE Exhibit 99.2 Convenience Translation. The German version is authoritative ARTICLES OF ASSOCIATION OF BIONTECH SE I.General Provisions § 1Company Name, Registered Office and Financial Year (1)The name of the Company is “BioNTech SE”. (2)The Company has its registered office in Mainz, Germany. (3)The financial year is the calendar year. § 2Purpose of Enterprise (1)The purpose of the Company is the r |
|
| November 4, 2024 |
BioNTech Announces Third Quarter 2024 Financial Results and Corporate Update Exhibit 99.1 BioNTech Announces Third Quarter 2024 Financial Results and Corporate Update •Presented clinical data for multiple assets across modalities, including bispecific antibody candidate BNT327/PM8002 and mRNA cancer vaccine candidate BNT113 based on BioNTech’s FixVac platform •Initiated two Phase 2 dose optimization trials with BNT327/PM8002 in small-cell lung cancer and in triple-negative |
|
| November 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF NOVEMBER 2024 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant’s name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal execut |
|
| November 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF NOVEMBER 2024 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant’s name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal execut |
|
| November 4, 2024 |
3rd Quarter 2024 Financial Results & Corporate Update November 4, 2024 Exhibit 99. |
|
| November 4, 2024 |
A C T I N G T O G E T H E R — C R E A T I N G S Y N E R G I E S Exhibit 99.1 BioNTech SE Quarterly Report of BioNTech SE for the three and nine months ended September 30, 2024 A C T I N G T O G E T H E R — C R E A T I N G S Y N E R G I E S Exhibit 99.1 Our principal executive offices are located at An der Goldgrube 12, D-55131 Mainz, Germany. Our telephone number is +49 6131-9084-0. Our website address is www.biontech.com. The information contained on, or that |
|
| October 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF OCTOBER 2024 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant’s name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal executi |
|
| October 1, 2024 |
BioNTech Highlights AI Capabilities and R&D Use Cases at Inaugural AI Day Exhibit 99.1 BioNTech Highlights AI Capabilities and R&D Use Cases at Inaugural AI Day •Provides updates on BioNTech’s strategy to scale and deploy AI-capabilities across the immunotherapy pipeline •Highlights InstaDeep’s new near exascale supercomputer, Kyber, with the aim of enabling BioNTech to compute at scale •Unveils novel AI Bayesian Flow Network (“BFN”) models for protein sequence generati |
|
| October 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF OCTOBER 2024 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant’s name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal executi |
|
| October 1, 2024 |
a992aiday-vfinal1 Exhibit 99.2 2 I AI Day © 2024 InstaDeep Ltd. & BioNTech SE I October 2024 This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. In some cases, forward-looking statements can be identified by terminology such as “will,” “may,” “should,” “expects,” “intends,” “plans,” “aims,” “anticipates,” “be |
|
| September 20, 2024 |
Exhibit 99.1 Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron KP.2-adapted COVID-19 Vaccine in the European Union •Upon authorization by the European Commission, the Omicron KP.2-adapted COVID-19 vaccine will be available for individuals 6 months of age and older •Data demonstrate that the Omicron KP.2-adapted COVID-19 vaccine generates a substantially improved response against multip |
|
| September 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF SEPTEMBER 2024 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant’s name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal execu |
|
| September 5, 2024 |
Exhibit 99.1 BioNTech to Present Clinical Data Updates Across mRNA and Immunomodulatory Oncology Portfolio at ESMO Congress 2024 MAINZ, Germany, September 05, 2024 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present clinical trial data for selected assets from its multi-platform oncology pipeline at the European Society for Molecular Oncology (“ESMO”) Congress 2024 in Barcelona, |
|
| September 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF SEPTEMBER 2024 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant’s name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal execu |
|
| August 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF AUGUST 2024 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant’s name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal executiv |
|
| August 22, 2024 |
Exhibit 99.1 Pfizer and BioNTech Receive U.S. FDA Approval & Authorization for Omicron KP.2-adapted COVID-19 Vaccine •The updated COVID-19 vaccine is tailored to the KP.2 strain of the SARS-CoV-2 Omicron JN.1 lineage and is recommended for individuals 6 months of age and older •The KP.2 adaptation is based on FDA guidance, which stated that KP.2 is the preferred strain for COVID-19 vaccines for th |
|
| August 19, 2024 |
Lift of Partial Clinical Hold for BNT326/YL202 Exhibit 99.1 Lift of Partial Clinical Hold for BNT326/YL202 On August 15, 2024, the U.S. Food and Drug Administration (“FDA”) lifted the partial clinical hold that was placed on MediLink Therapeutics’ (Suzhou) Co., Ltd. (“MediLink”) Phase I trial evaluating BNT326/YL202 (NCT05653752), which was announced on June 17, 2024. The complete response including data analysis, updated investigator brochure |
|
| August 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF AUGUST 2024 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant’s name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal executiv |
|
| August 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF AUGUST 2024 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant’s name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal executiv |
|
| August 16, 2024 |
Exhibit 99.1 Pfizer and BioNTech Provide Update on mRNA-based Combination Vaccine Program Against Influenza and COVID-19 in Individuals 18-64 Years of Age •In a Phase 3 trial, Pfizer and BioNTech’s combination vaccine candidate against influenza and COVID-19 met one of its two primary immunogenicity objectives •The trial did not meet one of its primary immunogenicity objectives of non-inferiority |
|
| August 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF AUGUST 2024 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant’s name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal executiv |
|
| August 5, 2024 |
BioNTech Announces Second Quarter 2024 Financial Results and Corporate Update Exhibit 99.1 BioNTech Announces Second Quarter 2024 Financial Results and Corporate Update •Announced positive data from multiple mRNA cancer vaccine clinical trials, including topline results from the ongoing Phase 2 evaluating FixVac candidate BNT111 •Launched updated variant-adapted COVID-19 vaccine in the European Union (“EU”), received approval in the United Kingdom and initiated rolling supp |
|
| August 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF AUGUST 2024 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant’s name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal executiv |
|
| August 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF AUGUST 2024 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant’s name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal executiv |
|
| August 5, 2024 |
A C T I N G T O G E T H E R — C R E A T I N G S Y N E R G I E S Exhibit 99.1 BioNTech SE Quarterly Report of BioNTech SE for the three and six months ended June 30, 2024 A C T I N G T O G E T H E R — C R E A T I N G S Y N E R G I E S Exhibit 99.1 Our principal executive offices are located at An der Goldgrube 12, D-55131 Mainz, Germany. Our telephone number is +49 6131-9084-0. Our website address is www.biontech.com. The information contained on, or that can b |
|
| August 5, 2024 |
2nd Quarter 2024 Financial Results & Corporate Update August 5, 2024 Exhibit 99.2 This Slide Presentation Includes Forward-Looking Statements 2 This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: BioNTech’s expected revenues and net profit/(loss) related t |
|
| July 30, 2024 |
Exhibit 99.1 BioNTech Announces Positive Topline Phase 2 Results for mRNA Immunotherapy Candidate BNT111 in Patients with Advanced Melanoma •Primary endpoint met in a Phase 2 trial evaluating the investigational mRNA immunotherapy BNT111 in combination with the PD-1 checkpoint inhibitor cemiplimab •Data demonstrated a statistically significant improvement of overall response rate (“ORR”) compared |
|
| July 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF JULY 2024 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant’s name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal executive |
|
| June 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF JUNE 2024 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant’s name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal executive |
|
| June 28, 2024 |
Exhibit 99.1 Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron JN.1-adapted COVID-19 Vaccine in the European Union •The updated COVID-19 vaccine is tailored to the Omicron JN.1 lineage of SARS-CoV-2 and is recommended for individuals 6 months of age and older •Recommendation is based on pre-clinical and epidemiological data showing that the JN.1-adapted monovalent COVID-19 vaccine gene |
|
| June 24, 2024 |
Exhibit 99.1 BioNTech and DualityBio Receive FDA Fast Track Designation for Antibody-Drug Conjugate Candidate BNT324/DB-1311 in Prostate Cancer •Designation is based on pre-clinical data and data from an ongoing Phase 1/2 trial for BNT324/DB-1311, with antitumor activity and a manageable safety profile demonstrated by preliminary Phase 1/2 clinical data from patients with advanced or metastatic so |
|
| June 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF JUNE 2024 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant’s name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal executive |
|
| June 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF JUNE 2024 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant’s name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal executive |
|
| June 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF JUNE 2024 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant’s name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal executive |
|
| June 3, 2024 |
Exhibit 99.1 Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC) •Initial data from the ongoing Phase 2 trial showed a 12-month overall survival rate of 69% and a median overall survival of 17.5 months in patients with previ |
|
| May 30, 2024 |
BioNTech and CEPI Expand Partnership to Strengthen Africa’s mRNA Vaccine Ecosystem Exhibit 99.1 BioNTech and CEPI Expand Partnership to Strengthen Africa’s mRNA Vaccine Ecosystem •BioNTech and CEPI aim to enhance local R&D, clinical and commercial-scale manufacturing capacities to develop potential mRNA vaccines in Africa, for Africa •CEPI to fund up to $145 million to support BioNTech in broadening the scope of the manufacturing facility in Kigali, Rwanda, aimed at addressing n |
|
| May 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF MAY 2024 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant’s name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal executive o |
|
| May 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF MAY 2024 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant’s name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal executive o |
|
| May 21, 2024 |
Exhibit 99.1 BioNTech to Present Clinical Data Updates for Next-Generation Immunotherapy Candidates at the ASCO Annual Meeting 2024 MAINZ, Germany, May 21, 2024 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present clinical trial data for selected programs from the Company’s diversified immuno-oncology pipeline at the American Society of Clinical Oncology (“ASCO”) Annual Meeting i |
|
| May 17, 2024 |
BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2024 Exhibit 99.1 BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2024 MAINZ, Germany, May 17, 2024 (GLOBE NEWSWIRE) — BioNTech SE (Nasdaq: BNTX, “BioNTech” or the “Company”) held its Annual General Meeting (“AGM”) today, May 17, 2024. A total of 87.51 per cent of the share capital was represented at the virtual assembly. There were 14 items on the agenda of the AGM. All |
|
| May 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF MAY 2024 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant’s name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal executive o |
|
| May 17, 2024 |
Voting results - Overview BioNTech SE, Mainz ordinary Annual General Meeting on 17/05/2024 Page 1Note: Percentages rounded to 2 decimal places Valid votes cast Yes votes No votes Shares % of capital stock Shares % Shares % Item 2 Resolution on the Appropriation of Balance Sheet Profit for the 2023 Financial Year 217,475,666 87. |
|
| May 17, 2024 |
Annual General Meeting (AGM) 17 May 2024 Exhibit 99.2 Management Report 2 Financial Development 2023 & Q1 2024 und Financial Outlook 2024 Jens Holstein, Chief Financial Officer 1 Operations Development 2023 & Q1 2024 and Outlook 2024 Prof. Dr. Ugur Sahin, Chief Executive Officer & Co-Founder 1 Operations Development 2023 & Q1 2024 and Outlook 2024 Prof. Dr. Ugur Sahin, CEO & Co-Founder This Slide |
|
| May 6, 2024 |
BioNTech Announces First Quarter 2024 Financial Results and Corporate Update Exhibit 99.1 BioNTech Announces First Quarter 2024 Financial Results and Corporate Update •Advancing toward goal of ten or more potentially registrational trials running by the end of 2024: first patient dosed in Phase 3 clinical trial evaluating BNT323/DB-1303 in HR+ HER2-low chemotherapy-naïve metastatic breast cancer patients, and a second Phase 3 trial with BNT323/DB-1303 in recurrent endometr |
|
| May 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF MAY 2024 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant’s name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal executive o |
|
| May 6, 2024 |
The accompanying notes form an integral part of these interim consolidated financial statements. Exhibit 99.1 BioNTech SE Quarterly Report of BioNTech SE for the Three Months Ended March 31, 2024 Exhibit 99.1 Our principal executive offices are located at An der Goldgrube 12, D-55131 Mainz, Germany. Our telephone number is +49 6131-9084-0. Our website address is www.biontech.com. The information contained on, or that can be accessed through, our website is not part of this document. Our agent |
|
| May 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF MAY 2024 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant’s name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal executive o |
|
| May 6, 2024 |
1st Quarter 2024 Financial Results & Corporate Update May 6, 2024 Exhibit 99.2 This Slide Presentation Includes Forward-Looking Statements 2 This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: BioNTech’s expected revenues and net profit/(loss) related to s |
|
| April 8, 2024 |
Exhibit 99.1 Three-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy Candidate Show Persistence of Immune Response and Delayed Tumor Recurrence in Some Patients with Resected Pancreatic Cancer •Three-year follow-up data of an investigator-initiated Phase 1 trial of the individualized mRNA cancer vaccine candidate autogene cevumeran (BNT122, RO7198457) continue to show polyspe |
|
| April 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF APRIL 2024 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant’s name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal executive |
|
| April 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF APRIL 2024 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant’s name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal executive |
|
| April 8, 2024 |
BioNTech SE Mainz WKN A0V9BC | ISIN DE000A0V9BC4 WKN: A2PSR2 | ISIN: US09075V1026 Invitation to the Annual General Meeting 2024 Unique identifier of the event: 2008339965e7ee11b53000505696f23c Ladies and Gentlemen, We hereby invite our shareholders1 to the Annual General Meeting of BioNTech SE, Mainz, (the “Company”) on Friday, May 17, 2024 at 2:00 p. |
|
| March 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF MARCH 2024 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant’s name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal executive |
|
| March 20, 2024 |
Consent of Independent Registered Public Accounting Firm Exhibit 15.1 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the following Registration Statements: (1)Registration Statement (Form S-8 No. 333-253263) pertaining to the 2020 Employee Equity Plan, the 2020 Restricted Stock Unit Plan for North America Employees, the 2017 Employee Stock Ownership Plan and the 2020 Management Board ESOP of BioN |
|
| March 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF MARCH 2024 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant’s name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal executive |
|
| March 20, 2024 |
BioNTech SE Compensation Clawback Policy Adopted November 29, 2023 BioNTech SE Compensation Clawback Policy Adopted November 29, 2023 Purpose The Supervisory Board (the “Board”) of BioNTech SE (the “Corporation”) has adopted this compensation clawback policy (the “Policy”) which provides for the recoupment of incentive-based compensation in the event of an accounting restatement. |
|
| March 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF |
|
| March 20, 2024 |
Exhibit 4.51 [***] Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) the type of information that the Registrant treats as private or confidential. Execution Version Confidential LICENSE AND COLLABORATION AGREEMENT by and between DUALITY BIOLOGICS (SUZHOU) CO. LTD. and BIONTECH SE dated as of March 31, 2023 TABLE OF CONTENTS ARTICL |
|
| March 20, 2024 |
BioNTech Announces Fourth Quarter and Full Year 2023 Financial Results and Corporate Update Exhibit 99.1 BioNTech Announces Fourth Quarter and Full Year 2023 Financial Results and Corporate Update •Advanced oncology pipeline in mid- and late-stage with plans to have ten or more potentially registrational oncology trials running by the end of 2024 •Aiming for first oncology launch in 2026 and ten indication approvals by 2030 as part of BioNTech's strategy to develop combinatorial and syne |
|
| March 20, 2024 |
BioNTech Announces Appointment of Annemarie Hanekamp to Management Board as Chief Commercial Officer Exhibit 99.1 BioNTech Announces Appointment of Annemarie Hanekamp to Management Board as Chief Commercial Officer Mainz, Germany, March 20, 2024 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today that the Supervisory Board has appointed Annemarie Hanekamp to the Management Board as Chief Commercial Officer effective July 1, 2024. She will join BioNTech from |
|
| March 20, 2024 |
Exhibit 4.54 [***] Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) is the type of information that the Registrant treats as private or confidential. LICENSE AND OPTION AGREEMENT BY AND AMONG AUTOLUS LIMITED AUTOLUS HOLDINGS (UK) LIMITED AND BIONTECH SE 299246678 v1 TABLE OF CONTENTS Page 1......... Definitions. 1 2......... Scope |
|
| March 20, 2024 |
Exhibit 4.47 [***] Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) the type of information that the Registrant treats as private or confidential. DATE: 31 July 2023 DEED OF AMENDMENT OF A SHARE PURCHASE AGREEMENT DATED 10 JANUARY 2023 Between THE FME SHAREHOLDERS' REPRESENTATIVE THE INVESTOR SELLERS' REPRESENTATIVE THE INSTITUTIO |
|
| March 20, 2024 |
Exhibit 13.2 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 The certification set forth below is being submitted in connection with the Annual Report on Form 20-F for the year ended 2023 (the “Report”) for the purpose of complying with Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 (the “Exchange Act”) |
|
| March 20, 2024 |
AMENDMENT No. 1 to the License and Collaboration Agreement between BioNTech SE and OncoC4, Inc. Exhibit 4.49 [***] Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) the type of information that the Registrant treats as private or confidential. CONFIDENTIAL AMENDMENT No. 1 to the License and Collaboration Agreement between BioNTech SE and OncoC4, Inc. This Amendment No. 1 to the License and Collaboration Agreement (this “Amend |
|
| March 20, 2024 |
LICENSE AND COLLABORATION AGREEMENT Exhibit 4.48 [***] Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) the type of information that the Registrant treats as private or confidential. EXECUTION VERSION CONFIDENTIAL LICENSE AND COLLABORATION AGREEMENT This License and Collaboration Agreement (this “Agreement”), effective as of March 17, 2023 (the “Execution Date”), is |
|
| March 20, 2024 |
Exhibit 4.50 [***] Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) the type of information that the Registrant treats as private or confidential. Confidential LICENSE AND COLLABORATION AGREEMENT by and between DUALITY BIOLOGICS (SUZHOU) CO. LTD. and BIONTECH SE dated as of March 16, 2023 Confidential TABLE OF CONTENTS ARTICLE 1 D |
|
| March 20, 2024 |
Exhibit 12.1 CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Ugur Sahin, certify that: 1.I have reviewed this annual report on Form 20-F of BioNTech SE; 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fa |
|
| March 20, 2024 |
Exhibit 12.2 CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Jens Holstein, certify that: 1.I have reviewed this annual report on Form 20-F of BioNTech SE; 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material |
|
| March 20, 2024 |
Exhibit 4.53 [***] Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) the type of information that the Registrant treats as private or confidential. Execution Version Dated 26 October 2023 BIOTHEUS INC. (普米斯生物技术(珠海)有限公司) (1) AND BIONTECH SE (2) COLLABORATION, LICENSE AND OPTION AGREEMENT CONTENTS Clause Heading Page 1 DEFINITIONS .. |
|
| March 20, 2024 |
Exhibit 4.52 [***] Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) the type of information that the Registrant treats as private or confidential. Execution Version Confidential LICENSE AND COLLABORATION AGREEMENT (TROP2) by and between DUALITY BIOLOGICS (SUZHOU) CO. LTD. and BIONTECH SE dated as of August 4, 2023 TABLE OF CONTENT |
|
| March 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF MARCH 2024 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant’s name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal executive |
|
| March 20, 2024 |
Exhibit 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 The certification set forth below is being submitted in connection with the Annual Report on Form 20-F for the year ended 2023 (the “Report”) for the purpose of complying with Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 (the “Exchange Act”) |
|
| March 20, 2024 |
ex99bntxq4fy2023xpresen 4th Quarter 2023 Financial Results & Corporate Update March 20, 2024 Exhibit 99. |
|
| March 20, 2024 |
Exhibit 2.4 DESCRIPTION OF SECURITIES The following description sets forth certain material terms and provisions of ordinary shares and American Depositary Shares representing ordinary shares of BioNTech SE (“BioNTech,” the “Company,” “we,” “us,” and “our”) that are registered under Section 12 of the U.S. Securities Exchange Act of 1934, as amended. This description also summarizes certain provisi |
|
| March 11, 2024 |
Exhibit 99.1 BioNTech to Present Clinical Data Updates For Personalized mRNA-based and Targeted Oncology Candidates at AACR 2024 MAINZ, Germany, March 11, 2024 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present clinical trial data for selected candidates from its oncology pipeline at the American Association for Cancer Research (“AACR”) Annual Meeting 2024 in San Diego, Califor |
|
| March 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF MARCH 2024 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant’s name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal executive |
|
| March 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF MARCH 2024 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant’s name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal executive |
|
| March 7, 2024 |
BioNTech Announces Planned Retirement of Sean Marett Exhibit 99.1 BioNTech Announces Planned Retirement of Sean Marett Mainz, Germany, March 7, 2024 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today that Sean Marett, Chief Business and Commercial Officer, will retire as planned from the Management Board of BioNTech. As of July 1, 2024, Sean Marett will continue as a specialist advisor to the Company at least |
|
| February 21, 2024 |
SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Autolus Therapeutics plc (Name of Issuer) Ordinary shares, nominal value $0.000042 per share (including ordinary shares represented by American Depositary Shares)** (Title of Class of Securities) 05280R100*** (CUSIP Number) Prof. Ugur Sahin, M.D. A |
|
| February 15, 2024 |
ARTICLES OF ASSOCIATION OF BIONTECH SE Exhibit 4.1 Convenience Translation. The German version is authoritative ARTICLES OF ASSOCIATION OF BIONTECH SE I.General Provisions § 1Company Name, Registered Office and Financial Year (1)The name of the Company is “BioNTech SE”. (2)The Company has its registered office in Mainz, Germany. (3)The financial year is the calendar year. § 2Purpose of Enterprise (1)The purpose of the Company is the re |
|
| February 15, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) BioNTech SE (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title(1) Fee Calculation Rule Amount Registered(2) Proposed Maximum Offering Price Per Unit(5) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Ordinary shares, no par value per share Equity —2024 Non-North America Employee Participation Plan Other 6,700,000(3) $94. |
|
| February 15, 2024 |
Exhibit 4.6 BioNTech SE 2024 NORTH AMERICA EMPLOYEE PARTICIPATION PLAN EFFECTIVE FEBRUARY 15, 2024 TABLE OF CONTENTS ARTICLE 1 ADMINISTRATION 1 ARTICLE 2 ELIGIBILITY 1 ARTICLE 3 PLAN VOLUME AND GRANT OF RSUs 1 ARTICLE 4 TREATMENT UPON TERMINATION 2 ARTICLE 5 SETTLEMENT 2 ARTICLE 6 TRANSFERABILITY, BENEFICIARIES, AND SHAREHOLDER RIGHTS 3 ARTICLE 7 CHANGE IN CONTROL 4 ARTICLE 8 ADJUSTMENT IN CASE OF |
|
| February 15, 2024 |
As filed with the Securities and Exchange Commission on February 15, 2024 As filed with the Securities and Exchange Commission on February 15, 2024 Registration No. |
|
| February 15, 2024 |
Exhibit 4.5 BioNTech SE 2024 NON-NORTH AMERICA EMPLOYEE PARTICIPATION PLAN EFFECTIVE FEBRUARY 15, 2024 TABLE OF CONTENTS ARTICLE 1 ADMINISTRATION 1 ARTICLE 2 ELIGIBILITY 1 ARTICLE 3 PLAN VOLUME AND GRANT OF RSUs 1 ARTICLE 4 TREATMENT UPON TERMINATION 2 ARTICLE 5 SETTLEMENT 2 ARTICLE 6 TRANSFERABILITY, BENEFICIARIES, AND SHAREHOLDER RIGHTS 3 ARTICLE 7 CHANGE IN CONTROL 4 ARTICLE 8 ADJUSTMENT IN CAS |
|
| February 14, 2024 |
DE:BNTX / BioNTech SE / Medine GmbH - SC 13G/A Passive Investment SC 13G/A 1 d754017dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* BIONTECH SE (Name of Issuer) Ordinary Shares, no par value per share (€1.00 nominal amount) (including Ordinary Shares represented by American Depositary Shares) (Title of Class of Securities) 09075V102** (CUSIP Nu |
|
| February 8, 2024 |
Exhibit 99.1 BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs •Strategic alliance leverages manufacturing and commercial infrastructure as well as technology with the aim to advance both companies’ autologous CAR-T programs towards market, pending market authorization •BioNTech secures the right to utilize Autolus’ manufact |
|
| February 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF FEBRUARY 2024 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant’s name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal execut |
|
| February 7, 2024 |
DE:BNTX / BioNTech SE / ATHOS KG - SC 13G/A Passive Investment SC 13G/A 1 d769040dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* BIONTECH SE (Name of Issuer) Ordinary Shares, no par value per share (€1.00 nominal amount) (including Ordinary Shares represented by American Depositary Shares) (Title of Class of Securities) 09075V102** (CUSIP Nu |
|
| January 31, 2024 |
Exhibit 99.1 BioNTech and DualityBio Receive FDA Fast Track Designation for Next-Generation Antibody-Drug Conjugate Candidate BNT325/DB-1305 •Designation is based on preliminary safety and efficacy data from an ongoing Phase 1/2 trial in patients with platinum-resistant ovarian epithelial cancer, fallopian tube, or primary peritoneal cancer1 •Fast Track designation can facilitate the development a |
|
| January 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF JANUARY 2024 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant’s name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal executi |
|
| January 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF JANUARY 2024 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant’s name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal executi |
|
| January 22, 2024 |
Exhibit 99.1 BioNTech and DualityBio Initiate Pivotal Phase 3 Trial Of Antibody-Drug Conjugate Candidate BNT323/DB-1303 in Metastatic Breast Cancer •The pivotal Phase 3 trial with BNT323/DB-1303 follows positive Phase 1/2 safety and efficacy data in patients with Human Epidermal Growth Factor Receptor 2 (“HER2”)-expressing advanced solid tumors with early signs of anti-tumor activity in heavily pr |
|
| January 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF JANUARY 2024 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant’s name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal executi |
|
| January 9, 2024 |
a992jpm2024presentation 42nd J.P. Morgan Healthcare Conference Prof. Ugur Sahin, M.D. CEO & Co-founder 9 January 2024 – 9:40 AM PST Exhibit 99.2 This Slide Presentation Includes Forward-Looking Statements 2 This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concernin |
|
| January 9, 2024 |
BioNTech Outlines 2024 Strategic Priorities at the 42nd Annual J.P. Morgan Healthcare Conference Exhibit 99.1 BioNTech Outlines 2024 Strategic Priorities at the 42nd Annual J.P. Morgan Healthcare Conference •Plans to have ten or more potentially registrational trials by the end of 2024 •Preparing to be commercial-ready by the end of 2025 •Ended 2023 with approximately €17.5 billion (unaudited) in cash, cash equivalents and security investments •Expects full year 2024 revenues of approximately |
|
| December 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF DECEMBER 2023 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant’s name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal execut |
|
| December 21, 2023 |
Exhibit 99.1 BioNTech and DualityBio Receive FDA Breakthrough Therapy Designation for Antibody-Drug Conjugate Candidate BNT323/DB-1303 in Endometrial Cancer •Designation is based on Phase 1/2 safety and efficacy data in patients with Human Epidermal Growth Factor Receptor 2 (“HER2”)-expressing advanced endometrial cancer with encouraging early signs of anti-tumor activity •Breakthrough Therapy des |
|
| December 18, 2023 |
BioNTech Achieves Milestone at mRNA-based Vaccine Manufacturing Site in Rwanda Exhibit 99.1 BioNTech Achieves Milestone at mRNA-based Vaccine Manufacturing Site in Rwanda •Set-up of first BioNTainer as high-tech manufacturing solution for mRNA medicines is a critical step in establishing a resilient vaccine ecosystem in Africa and future pandemic preparedness •BioNTech plans to complete all buildings at the Kigali site and start local training of specialized personnel in the |
|
| December 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF DECEMBER 2023 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant’s name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal execut |
|
| December 8, 2023 |
Exhibit 99.1 BioNTech and Australia’s State of Victoria Sign Agreement on Strategic Partnership to Strengthen mRNA Ecosystem •Multi-year partnership is aimed at strengthening the mRNA ecosystem in the State of Victoria by supporting the development of innovative medicines from research to application in the clinic •BioNTech will set up and operate a clinical-scale mRNA manufacturing facility throu |
|
| December 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF DECEMBER 2023 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant’s name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal execut |
|
| November 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF NOVEMBER 2023 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant’s name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal execut |
|
| November 7, 2023 |
Innovation Series 2023 November 7, 2023 9:00 AM – 1:00 PM ET 1 Welcome & Introductory Remarks Ryan Richardson Chief Strategy Officer This Slide Presentation Includes Forward-Looking Statements 3 This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: BioNTech' |
|
| November 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF NOVEMBER 2023 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant’s name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal execut |
|
| November 6, 2023 |
3rd Quarter 2023 Financial Results & Corporate Update November 6, 2023 This Slide Presentation Includes Forward-Looking Statements 2 This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: BioNTech's expected revenues and net profit related to sales of BioNTec |
|
| November 6, 2023 |
The accompanying notes form an integral part of these interim consolidated financial statements. Exhibit 99.1 BioNTech SE Quarterly Report of BioNTech SE for the Three And Nine Months Ended September 30, 2023 Exhibit 99.1 Our principal executive offices are located at An der Goldgrube 12, D-55131 Mainz, Germany. Our telephone number is +49 6131-9084-0. Our website address is www.biontech.com. The information contained on, or that can be accessed through, our website is not part of this docume |
|
| November 6, 2023 |
BioNTech Announces Third Quarter 2023 Financial Results and Corporate Update Exhibit 99.1 BioNTech Announces Third Quarter 2023 Financial Results and Corporate Update •Positive clinical data updates across multiple drug classes including antibody-drug conjugate (ADC) candidates BNT323/DB-1303, BNT325/DB-1305, CAR-T candidate BNT211, T cell therapy candidate BNT221 and mRNA cancer vaccine candidate BNT116 •Progress across the oncology pipeline with multiple late-stage trial |
|
| November 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF NOVEMBER 2023 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant’s name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal execut |
|
| October 26, 2023 |
Exhibit 99.1 ` Pfizer and BioNTech Announce Positive Topline Data for mRNA-based Combination Vaccine Program Against Influenza and COVID-19 •Lead formulations evaluated in the Phase 1/2 study demonstrated robust immune responses to influenza A, influenza B, and SARS-CoV-2 strains •Safety profile of the mRNA-based combination vaccine candidates consistent with the companies’ COVID-19 vaccine •The c |
|
| October 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF OCTOBER 2023 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant’s name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal executi |
|
| October 23, 2023 |
Exhibit 99.1 BioNTech Presents Positive Phase 1/2 Data Update for CAR-T Cell Therapy Candidate BNT211 in Advanced Solid Tumors at ESMO Congress 2023 •BNT211 combines two innovative approaches in one regimen with first-in-class potential: an autologous CAR-T cell therapy targeting the oncofetal antigen Claudin-6 (CLDN6) and a CLDN6-encoding CAR-T cell amplifying RNA vaccine (“CARVac”) •Data present |
|
| October 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF OCTOBER 2023 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant’s name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal executi |
|
| October 16, 2023 |
Update Regarding Pfizer’s Statement on COMIRNATY-Related Write-Offs Exhibit 99.1 Update Regarding Pfizer’s Statement on COMIRNATY-Related Write-Offs MAINZ, Germany, October 16, 2023 (GLOBE NEWSWIRE) - On October 13, 2023, Pfizer Inc. (NYSE: PFE, “Pfizer”), a collaboration partner of BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”), announced a non-cash charge for inventory write-offs and other charges related to COMIRNATY of $0.9 billion. The Company has be |
|
| October 16, 2023 |
BioNTech to Present Multiple Program Updates Across Modalities at ESMO Congress 2023 Exhibit 99.1 BioNTech to Present Multiple Program Updates Across Modalities at ESMO Congress 2023 •Program updates include new data for investigational CAR-T and ex-vivo T cell therapies, a novel ADC, a FixVac off-the-shelf mRNA cancer vaccine, and a bi-specific antibody •New data from BioNTech’s investigational autologous CAR-T therapy BNT211 demonstrate the potential of the Company’s innovative |
|
| October 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF OCTOBER 2023 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant’s name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal executi |
|
| October 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF OCTOBER 2023 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant’s name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal executi |
|
| September 11, 2023 |
Pfizer and BioNTech Receive U.S. FDA Approval for 2023-2024 COVID-19 Vaccine Exhibit 99.1 Pfizer and BioNTech Receive U.S. FDA Approval for 2023-2024 COVID-19 Vaccine •This season’s vaccine is tailored to the SARS-CoV-2 XBB.1.5 sublineage and indicated as a single dose for most individuals 5 years of age and older •Pre-clinical data show that the updated COVID-19 vaccine generates improved neutralizing antibody responses against multiple circulating Omicron-related subline |
|
| September 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF SEPTEMBER 2023 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant’s name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal execu |
|
| August 30, 2023 |
Exhibit 99.1 Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron XBB.1.5-adapted COVID-19 Vaccine in the European Union •The updated COVID-19 vaccine is tailored to the Omicron XBB.1.5 sublineage of SARS-CoV-2 and is recommended for individuals 6 months of age and older •Recommendation is based on pre-clinical data showing that the Omicron XBB.1.5-adapted monovalent COVID-19 vaccine gene |
|
| August 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF AUGUST 2023 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant’s name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal executiv |
|
| August 14, 2023 |
BioNTech Expands Management Board by Appointing James Ryan as Chief Legal Officer Exhibit 99.1 BioNTech Expands Management Board by Appointing James Ryan as Chief Legal Officer MAINZ, Germany, August 14, 2023 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced that the Supervisory Board has appointed James Ryan, Ph.D., to the Management Board as Chief Legal Officer (CLO), effective September 1, 2023. As part of the Management Board, James Ryan will continue to l |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF AUGUST 2023 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant’s name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal executiv |
|
| August 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF AUGUST 2023 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant’s name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal executiv |
|
| August 7, 2023 |
BioNTech Announces Second Quarter 2023 Financial Results and Corporate Update Exhibit 99.1 BioNTech Announces Second Quarter 2023 Financial Results and Corporate Update •Significant pipeline advancement highlighted by the initiation of BNT316/ONC-392 Phase 3 pivotal trial and multiple trials planned to start across the oncology portfolio •Positive data updates across multiple technology platforms including ADC candidate BNT323/DB-1303, anti-CTLA4 monoclonal antibody candida |
|
| August 7, 2023 |
The accompanying notes form an integral part of these interim consolidated financial statements. Exhibit 99.1 BioNTech SE Quarterly Report of BioNTech SE for the Three And Six Months Ended June 30, 2023 Exhibit 99.1 Our principal executive offices are located at An der Goldgrube 12, D-55131 Mainz, Germany. Our telephone number is +49 6131-9084-0. Our website address is www.biontech.com. The information contained on, or that can be accessed through, our website is not part of this document. Ou |
|
| August 7, 2023 |
bntxq22023presentationf 2nd Quarter 2023 Financial Results & Corporate Update August 7, 2023 Exhibit 99. |
|
| August 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF AUGUST 2023 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant’s name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal executiv |
|
| July 31, 2023 |
BioNTech Completes Acquisition of InstaDeep Exhibit 99.1 BioNTech Completes Acquisition of InstaDeep •Acquisition aims to strengthen BioNTech’s pioneering position in the field of AI-powered drug discovery, design and development •InstaDeep to operate as London based subsidiary of BioNTech and will be the centerpiece of its growing portfolio of initiatives around artificial intelligence and machine learning •Approximately 290 highly skilled |
|
| July 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF JULY 2023 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant’s name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal executive |
|
| June 29, 2023 |
BioNTech and OncoC4 Initiate Pivotal Phase 3 Trial of BNT316/ONC-392 Program in Metastatic NSCLC Exhibit 99.1 BioNTech and OncoC4 Initiate Pivotal Phase 3 Trial of BNT316/ONC-392 Program in Metastatic NSCLC •Initiation of pivotal Phase 3 trial in non-small cell lung cancer (NSCLC) marks the first landmark in BioNTech’s and OncoC4’s strategic collaboration initiated in March 2023 with the aim to evaluate BNT316/ONC-392 in various solid tumor indications •The randomized Phase 3 trial is expecte |
|
| June 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF JUNE 2023 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant’s name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal executive |
|
| June 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF JUNE 2023 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant’s name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal executive |
|
| June 26, 2023 |
Exhibit 99.1 Pfizer and BioNTech Submit Applications to U.S. FDA for Omicron XBB.1.5-Adapted Monovalent COVID-19 Vaccine •The submissions reflect guidance from FDA and other major health authorities to provide COVID-19 vaccines better matched to currently circulating sublineages •The companies expect to be ready to ship the adapted vaccines immediately following regulatory authorization/approval N |
|
| June 23, 2023 |
Exhibit 99.1 Pfizer and BioNTech Initiate Application to European Medicines Agency for Omicron XBB.1.5-Adapted Monovalent COVID-19 Vaccine •The application reflects guidance from EMA and other major health authorities to provide COVID-19 vaccines better matched to currently circulating sublineages •The companies expect to be ready to ship the adapted vaccines to EU member states immediately follow |
|
| June 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF JUNE 2023 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant’s name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal executive |
|
| June 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF JUNE 2023 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant’s name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal executive |
|
| June 2, 2023 |
Exhibit 99.1 Disclosure of share buyback program pursuant to Art. 5(1) lit. a) of Regulation (EU) No. 596/2014 of the European Parliament and the Council of April 16, 2014 and Art. 2(1) of Delegated Regulation (EU) 2016/1052 of the European Commission of March 8, 2016 MAINZ, Germany, June 2, 2023 - On March 27, 2023, the Management Board of BioNTech SE (“BioNTech”), with the approval of the Superv |
|
| June 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF JUNE 2023 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant’s name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal executive |
|
| June 2, 2023 |
Exhibit 99.1 BioNTech and OncoC4 Present Positive Phase 1/2 Data for Antibody Candidate BNT316/ONC-392 in Hard-to-Treat NSCLC at ASCO •BNT316/ONC-392 is a next-generation anti-CTLA-4 monoclonal antibody candidate jointly developed by BioNTech and OncoC4 as monotherapy or combination therapy in a range of solid tumor indications, including non-small cell lung cancer (NSCLC) •Interim data of BNT316/ |
|
| May 26, 2023 |
Pfizer and BioNTech Provide Update on COVID-19 Vaccine Supply Agreement with the European Commission Exhibit 99.1 Pfizer and BioNTech Provide Update on COVID-19 Vaccine Supply Agreement with the European Commission NEW YORK and MAINZ, GERMANY, MAY 26, 2023 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have reached an agreement with the European Commission (EC) to amend their existing contract to deliver COVID-19 vaccines to the European Union. The amended agreement |
|
| May 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF MAY 2023 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant’s name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal executive o |
|
| May 25, 2023 |
Exhibit 99.1 Changes in the Supervisory Board of BioNTech SE and Voting Results from the Annual General Meeting 2023 •Baroness Nicola Blackwood newly appointed to Supervisory Board; Michael Motschmann and Ulrich Wandschneider, Ph.D. reappointed •Prof. Christoph Huber, M.D., leaves BioNTech’s Supervisory Board upon reaching retirement age limit; he will become a member in BioNTech’s scientific advi |
|
| May 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF MAY 2023 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant’s name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal executive o |
|
| May 25, 2023 |
ex993biontech-overviewv Voting results - Overview BioNTech SE, Mainz Ordinary Annual General Meeting on 25/05/2023 Page 1Note: Percentages rounded to 2 decimal places Item 2 Resolution on the Appropriation of Balance Sheet Profit for the 2021 Financial Year (adopted) 232,713,555 Shares for which valid votes were cast (= 93. |
|
| May 25, 2023 |
ex992biontechse2023agmp May 25, 2023 Annual General Meeting English Convenience Translation: German language is the official version. |
|
| May 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF MAY 2023 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant’s name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal executive o |
|
| May 8, 2023 |
The accompanying notes form an integral part of these interim consolidated financial statements. Exhibit 99.1 BioNTech SE Quarterly Report of BioNTech SE for the Three Months Ended March 31, 2023 Exhibit 99.1 Our principal executive offices are located at An der Goldgrube 12, D-55131 Mainz, Germany. Our telephone number is +49 6131-9084-0. Our website address is www.biontech.com. The information contained on, or that can be accessed through, our website is not part of this document. Our agent |
|
| May 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF MAY 2023 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant’s name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal executive o |
|
| May 8, 2023 |
ex992bntxq12023presenta 1st Quarter 2023 Financial Results & Corporate Update May 8, 2023 This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: BioNTech's expected revenues and net profit related to sales of BioNTech's COVID-19 vaccine, referred to as COMIRN |
|
| May 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF MAY 2023 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant’s name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal executive o |
|
| May 8, 2023 |
BioNTech Announces First Quarter 2023 Financial Results and Corporate Update Exhibit 99.1 BioNTech Announces First Quarter 2023 Financial Results and Corporate Update •COVID-19 vaccine franchise focused on vaccine adaptation readiness ahead of the fall season and advancing next generation vaccine candidates and combinations •BioNTech and partner OncoC4 plan to start a Phase 3 clinical trial evaluating anti-CTLA-4 antibody BNT316 (ONC-392) as monotherapy in NSCLC patients w |
|
| May 8, 2023 |
The accompanying notes form an integral part of these interim consolidated financial statements. Exhibit 99.1 BioNTech SE Quarterly Report of BioNTech SE for the Three Months Ended March 31, 2023 Exhibit 99.1 Our principal executive offices are located at An der Goldgrube 12, D-55131 Mainz, Germany. Our telephone number is +49 6131-9084-0. Our website address is www.biontech.com. The information contained on, or that can be accessed through, our website is not part of this document. Our agent |
|
| April 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF APRIL 2023 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant’s name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal executive |
|
| April 13, 2023 |
English Convenience Translation – Exhibit 99.1 the German language invitation is decisive BioNTech SE Mainz WKN A0V9BC | ISIN DE000A0V9BC4 Invitation to the Annual General Meeting 2023 Unique identifier of the event: 327fbe3ffdceed118145005056888925 Dear Sir or Madam1, We hereby invite you, as a shareholder of BioNTech SE, Mainz (the “Company”), to the Annual General Meeting to be held on Thursday |
|
| April 3, 2023 |
BioNTech and DualityBio Form Global Strategic Partnership to Accelerate Development of Differentiated Antibody-Drug Conjugate Therapeutics for Solid Tumors •BioNTech receives exclusive licenses from DualityBio for two investigational antibody-drug conjugate assets (DB-1303 and DB-1311) directed against targets expressed in a broad range of human cancers •Collaboration will add a new class of precision medicine therapeutics to BioNTech’s clinical-stage oncology portfolio, expanding the breadth of its immunotherapy toolkit with synergistic potential •DualityBio receives upfront payments totaling $170 million, and will be eligible to receive development, regulatory and commercial milestone payments potentially totaling over $1. |
|
| April 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF APRIL 2023 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant’s name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal executive |
|
| March 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF MARCH 2023 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant’s name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal executive |
|
| March 28, 2023 |
BioNTech Announces New ADS Repurchase Program Exhibit 99.1 BioNTech Announces New ADS Repurchase Program MAINZ, Germany, March 28, 2023 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or the “Company”) today announced that it has entered into a new share repurchase program (the “Program”), pursuant to which the Company may purchase American Depositary Shares, each representing one ordinary share (“ADS”), of the Company in the amount of up to $0.5 bil |
|
| March 27, 2023 |
EX-4.38 SENSITIVE Exhibit 4.38 THE SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED EUROPEAN COMMISSION Directorate-General for Health and Food Safety PURCHASE AGREEMENT (“PA”)1 for the further development, production, purchasin |
|
| March 27, 2023 |
Articles of Association of the Registrant EX-1.1 Exhibit 1.1 Convenience Translation. The German version is authoritative ARTICLES OF ASSOCIATION OF BIONTECH SE I. General Provisions § 1 Company Name, Registered Office and Financial Year (1) The name of the Company is “BioNTech SE”. (2) The Company has its registered office in Mainz, Germany. (3) The financial year is the calendar year. § 2 Purpose of Enterprise (1) The purpose of the Com |
|
| March 27, 2023 |
EX-4.34 Exhibit 4.34 THE SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED LEASE AGREEMENT THIS LEASE AGREEMENT (“this Lease”) is made as of this 1 day of December, 2017, between TECH PARK 270 Ill, LLC, a Maryland limited liabili |
